{"annotatable":{"parts":["s1v1","s2v1","s3v1","s4v1","s5v1","s6v1","s7v1","s8v1","s9v1","s10v1","s11v1","s12v1","s13v1","s14v1","s15v1","s16v1","s17v1","s18v1","s19v1","s20v1"]},"anncomplete":true,"sources":[],"metas":{"m_83":{"value":"Some-concerns","confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1}},"m_82":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1}},"m_84":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1}},"m_85":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1}},"m_86":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1}},"m_35":{"value":"Some-concerns","confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1}}},"entities":[{"classId":"e_215","part":"s1v1","offsets":[{"start":2991,"text":"Trial Registration: clinicaltrials.gov identifier: NCT00373724"}],"coordinates":[{"x":"90.00","y":"690.44"},{"x":"287.99","y":"695.70"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_210","part":"s1v1","offsets":[{"start":3011,"text":"clinicaltrials.gov identifier: NCT00373724"}],"coordinates":[{"x":"150.89","y":"690.44"},{"x":"287.99","y":"695.70"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_186","part":"s1v1","offsets":[{"start":3042,"text":"NCT00373724"}],"coordinates":[{"x":"239.99","y":"690.44"},{"x":"287.99","y":"695.70"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_112","part":"s3v1","offsets":[{"start":1362,"text":"Studypatients were randomized in a 1:1 ratio to receive either true or placebo denervation. A researchnurse not involved in patient care performed randomization in blocks of 4 via pre-sealedenvelopes at each institution."}],"coordinates":[{"x":"492.46","y":"286.99"},{"x":"266.10","y":"329.56"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_114","part":"s3v1","offsets":[{"start":1454,"text":"A researchnurse not involved in patient care performed randomization in blocks of 4 via pre-sealedenvelopes at each institution."}],"coordinates":[{"x":"479.77","y":"298.99"},{"x":"266.10","y":"329.56"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_126","part":"s4v1","offsets":[{"start":601,"text":"In the control group, electrodes were similarly positioned, electrostimulation was performedin an identical manner, and 0.5 ml of lidocaine 2% was administered, but no current wasadministered. The average time it took to perform the radiofrequency and placebo procedureswere comparable (a mean of 61 minutes vs. 54 minutes, respectively, for the first 5 people ineach group)."}],"coordinates":[{"x":"150.00","y":"156.80"},{"x":"199.98","y":"211.37"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_129","part":"s4v1","offsets":[{"start":794,"text":"The average time it took to perform the radiofrequency and placebo procedureswere comparable (a mean of 61 minutes vs. 54 minutes, respectively, for the first 5 people ineach group)."}],"coordinates":[{"x":"206.49","y":"180.80"},{"x":"199.98","y":"211.37"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_186","part":"s4v1","offsets":[{"start":3116,"text":"The primary outcome measure was a 0–10 NRS pain score, which reflected the average painexperienced by the patient for 10 days prior to follow-up. Secondary outcome measuresincluded Oswestry disability index (ODI version 2.0, MODEMS, Des Plaine, IL, reflecting the10 days prior to follow-up) score, reduction in analgesic medications (defined as a 20%reduction in opioid use or complete cessation of a non-opioid analgesic),16 GPE, and acomposite successful outcome. A positive GPE was defined as an affirmative response to thefollowing 3 questions:1. My pain has improved/ worsened/ stayed the same since my last visit;"}],"coordinates":[{"x":"150.00","y":"552.90"},{"x":"465.70","y":"649.47"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_210","part":"s4v1","offsets":[{"start":3128,"text":"outcome measure was a 0–10 NRS pain score"}],"coordinates":[{"x":"202.21","y":"552.90"},{"x":"385.23","y":"559.47"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_175","part":"s4v1","offsets":[{"start":3150,"text":"0–10 NRS pain score"}],"coordinates":[{"x":"299.96","y":"552.90"},{"x":"385.23","y":"559.47"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_151","part":"s5v1","offsets":[{"start":384,"text":"Statistical analyses were performed using STATA version 10.0 (Statcorp, College Station,TX). The Shapiro-Wilk W test for normal data was performed on continuous outcomemeasures. The distribution of categorical variables in each group was compared using Fisherexact test. Continuous variables are reported as mean and standard deviation or median andinterquartile range. Categorical data are reported by number of subjects and percentage.Comparisons between the initial radiofrequency treatment group and the placebo group weremade with unpaired t-tests or Mann-Whitney U test. Since the continuous data in each grouphad a normal distribution, comparisons between and within the initial radiofrequency andcrossover treatment groups were made with two-way analysis of variance (ANOVA). Formultiple significance testing, post-hoc Bonferroni correction was used. Because baseline ODIdifferences were a potential confounding factor, an adjusted multiple linear and logisticregression analysis was performed for each continuous and categorical outcome measure,respectively."}],"coordinates":[{"x":"150.00","y":"156.90"},{"x":"200.82","y":"307.47"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_215","part":"s5v1","offsets":[{"start":754,"text":"Categorical data are reported by number of subjects and percentage.Comparisons between the initial radiofrequency treatment group and the placebo group weremade with unpaired t-tests or Mann-Whitney U test. Since the continuous data in each grouphad a normal distribution, comparisons between and within the initial radiofrequency andcrossover treatment groups were made with two-way analysis of variance (ANOVA). Formultiple significance testing, post-hoc Bonferroni correction was used. Because baseline ODIdifferences were a potential confounding factor, an adjusted multiple linear and logisticregression analysis was performed for each continuous and categorical outcome measure,respectively."}],"coordinates":[{"x":"228.59","y":"204.90"},{"x":"200.82","y":"307.47"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_159","part":"s5v1","offsets":[{"start":1470,"text":"Data were analyzed on 28 patients."}],"coordinates":[{"x":"150.00","y":"362.98"},{"x":"289.96","y":"369.55"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_121","part":"s5v1","offsets":[{"start":1505,"text":"Demographic (including active duty status) and clinicalcharacteristics were balanced between the radiofrequency denervation treatment and controlgroup."}],"coordinates":[{"x":"292.46","y":"362.98"},{"x":"175.83","y":"393.55"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_139","part":"s5v1","offsets":[{"start":2275,"text":"Three patients in the placebo group declined to crossover to the radiofrequency denervationtreatment group. Among these 3 patients, one elected not to receive the true procedure becausethe placebo treatment was “too painful”, and 2 sought alternative care."}],"coordinates":[{"x":"150.00","y":"480.98"},{"x":"431.60","y":"511.55"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_186","part":"s5v1","offsets":[{"start":2275,"text":"Three patients in the placebo group declined to crossover to the radiofrequency denervationtreatment group. Among these 3 patients, one elected not to receive the true procedure becausethe placebo treatment was “too painful”, and 2 sought alternative care. Based on thedemographic and clinical characteristics, there appeared to be no difference between thesepatients and those who elected to cross-over."}],"coordinates":[{"x":"150.00","y":"480.98"},{"x":"329.13","y":"535.55"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_134","part":"s5v1","offsets":[{"start":2383,"text":"Among these 3 patients, one elected not to receive the true procedure becausethe placebo treatment was “too painful”, and 2 sought alternative care."}],"coordinates":[{"x":"217.56","y":"492.98"},{"x":"431.60","y":"511.55"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_146","part":"s5v1","offsets":[{"start":2383,"text":"Among these 3 patients, one elected not to receive the true procedure becausethe placebo treatment was “too painful”, and 2 sought alternative care."}],"coordinates":[{"x":"217.56","y":"492.98"},{"x":"431.60","y":"511.55"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_134","part":"s5v1","offsets":[{"start":2389,"text":"these 3 patients, one elected not to receive the true procedure becausethe placebo treatment was “too painful”, and 2 sought alternative care."}],"coordinates":[{"x":"249.54","y":"492.98"},{"x":"431.60","y":"511.55"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_203","part":"s5v1","offsets":[{"start":2702,"text":"A significant difference in the primary outcome, NRS pain score, was detected between thetreatment and placebo groups at follow-up (table 2). One month after the procedure, thetreatment group had significantly lower NRS scores than the placebo group (2.4 ± 2.0; range0–8 vs. 6.3 ± 2.4; range 2–10, p<0.001, respectively). In the placebo group, only 2 patients at1 month and no patients at 3 months reported a positive outcome. The primary outcomeremained significantly different between the two groups when baseline ODI scores wereanalyzed as a covariate (coefficient of variation −3.8, 95% CL −5.8 to −1.8; p<0.001). At 3and 6-month follow-up, 8 and 4 patients in the treatment group, respectively, reported NRSpain scores ≤ 2."}],"coordinates":[{"x":"150.00","y":"569.08"},{"x":"212.70","y":"671.65"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_191","part":"s7v1","offsets":[{"start":1738,"text":"A disinterested observer querying patients before discharge fromtheir procedure assessed the adequacy of blinding. In the 14 patients in the radiofrequencygroup, 9 thought they received denervation, 2 thought they received placebo treatment and 3were unable to guess which group they were randomized to despite prodding. In the 14 placebopatients, 8 believed they received radiofrequency denervation, 3 felt they received the placebotreatment and 3 were unsure which group they were randomized. In the radiofrequency group,the 11 successful outcomes at 1-month were comprised of 8 patients who thought they receiveddenervation, one who felt he received placebo treatment, and 2 patients who were unsure whichgroup they were allocated to. Both successful outcomes in the placebo-arm at 1-month thoughtthey received denervation."}],"coordinates":[{"x":"262.69","y":"349.08"},{"x":"255.80","y":"463.65"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_151","part":"s10v1","offsets":[{"start":753,"text":"H"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}},{"classId":"e_151","part":"s11v1","offsets":[{"start":1065,"text":"H"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}},{"classId":"e_156","part":"s12v1","offsets":[{"start":238,"text":"uthor M"}],"coordinates":[{"x":"145.94","y":"580.99"},{"x":"186.62","y":"589.16"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_121","part":"s16v1","offsets":[{"start":94,"text":"Table 1Demographic and Clinical Characteristics of Study Patients Placebo (n=14) Lateral Branch Denervation(n=14)Sex  Male (n=11) 6 (43%) 5 (36%)  Female (n=17) 8 (57%) 9 (64%)Age (SD, range) 51.8 (13.1; 31–74) 51.9 (13.6; 27–75)Active Duty (n=6) 3 (21%) 3 (21%)Opioid Use (n=13) and Dosage in Morphine 7 (50%) 6 (43%)Equivalents per Day (mean, SD, range) 46.4 (43.1, 7.5–130) 60 (50.0, 7.5–150)Worker’s Compensation, Disability, or Military Medical BoardClaim (n=9) 3 (21%) 6 (43%)*Failed Back Surgery Syndrome (n=6)** 4 (29%) 2 (14%)Baseline Numerical Rating Scale Score (SD, 6.5 (1.9; 3.5–10) 6.1 (1.8; 3–8)range) Median (interquartile range) 6 (5.5–7) 6 (5–8)Baseline Oswestry Disability Index (SD, 47.9 (9.3; 28–58) 37.1 (10.6; 18–49)range) 50.5 (44–56) 41 (26–46)"}],"coordinates":[{"x":"248.49","y":"61.96"},{"x":"485.37","y":"414.12"}],"confidence":{"state":"pre-added","who":["user:katia-giacomino"],"prob":1},"fields":{},"normalizations":{}}],"relations":[]}